VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Tuesday. The brokerage issued a sell rating on the stock.

Separately, Benchmark reissued a hold rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Price Performance

VNRX opened at $0.64 on Tuesday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The firm has a market capitalization of $58.48 million, a PE ratio of -1.42 and a beta of 1.12. The business’s 50-day moving average is $0.65 and its two-hundred day moving average is $0.72.

VolitionRx (NYSE:VNRX) last released its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.34 million. As a group, sell-side analysts expect that VolitionRx will post -0.31 EPS for the current year.

Insider Activity at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average price of $0.67 per share, for a total transaction of $100,500.00. Following the acquisition, the director now owns 406,683 shares in the company, valued at $272,477.61. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 12.80% of the stock is owned by insiders.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.